Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Aún no traducido Aún no traducido
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2017
Cargando información sobre las referencias
A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5\~.75 mg/day) to maintain platelet counts 50\~250×109/L
Epistemonikos ID: 702110625116c14e4fa9ee5887f6ed4b6fa6cd0c
First added on: May 20, 2024